Triazavirin®Active substance : Methylthionitrooxodihydrotriazolotriazinid is a synthetic analogue of the base of purine nucleosides (guanine) with a pronounced antiviral effect. It has a wide spectrum of antiviral activity against RNA-containing viruses.
The main mechanism of action of Triazavirin® is the inhibition of the synthesis of viral RNA and the replication of genomic fragments. Pharmacokinetics After ingestion Triazavirin® is rapidly absorbed in the gastrointestinal tract. The maximum concentration (C max) is reached in an average of 1-1.5 hours.
From 15 to 45% of the drug is excreted by the kidneys in unchanged form. The average calculated clearance is 246 ml / min.
IndicationsTreatment of influenza in adults. If necessary, combined with the reception of symptomatic agents.
- hypersensitivity to the drug;
- breastfeeding period;
- children's age up to 18 years (efficiency and safety are not defined);
- renal / hepatic impairment (efficacy and safety not determined).
Pregnancy and lactationThe use of the drug during pregnancy has not been studied. The use of the drug during lactation has not been studied, therefore, if necessary, use of the drug during lactation should stop breastfeeding.
Dosage and administrationTriazavirin® is applied inside regardless of the meal.
The drug should be started no later than the 2nd day from the onset of the disease (onset of clinical symptoms) 1 capsule (250 mg) 3 times a day (daily dose 750 mg) for 5 days. If necessary, treatment can be continued up to 7 days.
Name in Cyrillic : Триазавирин
250mg x 20 capsules
- Availability: In Stock